HYFT® technology computationally identified and prioritized a pan-serotype dengue target before immunization. Preclinical data support the prediction at the binding level: immunization with immunogens designed on the predicted target elicited antibodies that cross-react with antigens of all four dengue serotypes, and scrambled-sequence controls support that the response is specific to the designed immunogen rather than background reactivity.

MindWalk Holdings Corp. (NASDAQ:HYFT) today reported preclinical dengue data that support a computational prediction its HYFT® platform generated before any animal was immunized. HYFT® computationally identified a candidate pan-serotype structural target on the dengue virus. The subsequent immunization data support that prediction at the antibody-binding level: animals immunized with immunogens designed on the predicted target generated antibodies that cross-reacted with antigens of all four dengue serotypes — a clear and consistent trend, reproduced at the cohort level across two independent campaigns that used distinct immunogen formats and adjuvants. Scrambled-sequence controls did not show the same cross-serotype recognition, indicating the response was specific to the designed immunogen.

The result carries implications beyond the dengue program. AI-driven drug discovery depends on biological ground truth — experimentally grounded signal connecting a computational prediction to a measurable outcome in living systems. That substrate has been largely absent from the field: generated inconsistently, outside regulated frameworks, and rarely structured to meet the demands of enterprise AI deployment. The HYFT® platform is designed to produce it. Today's data are MindWalk's first public evidence that it can.

Today's data document the platform delivering on its fundamental claim: HYFT® technology computationally prioritized the pan-serotype target before immunization, the experiment supported the binding-level prediction, and the experimentally supported target now anchors MindWalk's dengue pipeline IP position as a persistent asset within the company's Biointelligence Platform. The same predictive capability applied in dengue is being deployed across MindWalk's influenza program and other announced programs where multi-strain coverage presents the analogous design challenge.